Alembic Pharma gets USFDA approval for flu drug

26 Jun 2026via The Economic TimesSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Alembic Pharma gets USFDA nod for generic influenza treatment drug. This approval allows the company to launch the generic version of a flu medication in the US market. Entry into the competitive US generics space could boost revenues by $50–70 million annually at peak. The stock may see positive momentum on export potential.

📊 STOCKS: APLLTD | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA

#USFDA#approval#generic#influenza

Stocks mentioned

APLLTDAPLLTD

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →